Aim: To investigate the potential involvement of the hepatic ATP-binding cassette
transporters MRP2 and MDR1 in the disposition of lumefantrine (LUM) among patients with …

Malaria treatment performance is potentially influenced by pharmacogenetic factors. This
study reports an association study between the ABCB1 c. 3435C> T, CYP3A4* 1B (g.-392A> …

Aim: We aimed to assess the effect of a functional polymorphism of CYP3A5 on lumefantrine
pharmacokinetics. Patients & methods: Sixty-nine women diagnosed with malaria received …

We investigated the influence of efavirenz (EFV)-or nevirapine (NVP)-based antiretroviral
therapy (ART) on lumefantrine plasma exposure in HIV-malaria-coinfected patients and …

The mechanisms of drug resistance development in the Plasmodium falciparum parasite to
lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We …

Background Pregnancy has considerable effects on the pharmacokinetic properties of drugs
used to treat uncomplicated Plasmodium falciparum malaria. The role of pharmacogenetic …

Background Despite efforts made to reduce morbidity and mortality associated with malaria,
especially in sub-Saharan Africa, malaria continues to be a public health concern that …

Background. Our study examined the relative contributions of host, pharmacokinetic, and
parasitological factors in determining the therapeutic response to artemether-lumefantrine …

Background Malaria/HIV co-infection (MHC) is a public health challenge which may present
with worse health outcomes due to interactions. Coadministration of artemether lumefantrine …

Pregnancy and pharmacogenetics variation alter drug disposition and treatment outcome.
The objective of this study was to investigate the effect of pregnancy and pharmacogenetics …